[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349558-105":59,"doc-detail-349558-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","expression-of-survivin-and-her-2-as-independent-predictive-factors-for-treatment-response-in-locally-advanced-breast-cancer-a-prospective-cohort-study","Expression of Survivin and HER-2 as Independent Predictive Factors for Treatment Response in Locally Advanced Breast Cancer - A Prospective Cohort Study","","Locally advanced breast cancer (LABC) requires multimodal management, often beginning with neoadjuvant chemotherapy (NACT), yet patient response varies widely. This prospective cohort study evaluates whether Survivin and HER-2 expression can predict clinical response to NACT in 56 female LABC patients. Pre-treatment biopsy tissues were assessed by immunohistochemistry, and response after three cycles was determined using RECIST. High Survivin and HER-2 positivity correlated with poor chemotherapy response and remained independent predictors in multivariate analysis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/expression-of-survivin-and-her-2-as-independent-predictive-factors-for-treatment-response-in-locally-advanced-breast-cancer-a-prospective-cohort-study/349558/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/expression-of-survivin-and-her-2-as-independent-predictive-factors-for-treatment-response-in-locally-advanced-breast-cancer-a-prospective-cohort-study/349558.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study?","Question",{"text":112,"@type":113},"To analyze the relationship between Survivin and HER-2 expression and the clinical response to NACT in locally advanced breast cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were Survivin and HER-2 expression levels measured?",{"text":117,"@type":113},"Pre-treatment biopsy tissues were examined for Survivin and HER-2 expression using immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"How was treatment response assessed after NACT?",{"text":121,"@type":113},"Clinical response was evaluated after three chemotherapy cycles using the RECIST criteria.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349558,1790819576,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","RESEARCH ARTICLE  \n\n| Editorial Proc | ess: Submission:06/28/2025 Acceptance:01/27/2026 Published:02/06/2026 |\n| --- | --- |\n\nExpression of Survivin and HER-2 as Independent Predictive Factors for Treatment Response in Locally Advanced Breast Cancer: A Prospective Cohort Study  \nSan Winata Badiri1, Indra Indra1, Elridho Sampepajung1, John Pieter Jr1, Berti J. Nelwan2, Djonny Ferianto1, Salman Ardi Syamsu1, Muhammad Faruk1 *  \nAbstract  \nBackground: Locally advanced breast cancer (LABC) requires a multimodal approach, often starting with neoadjuvant chemotherapy (NACT) to reduce tumor size. However, response to NACT in LABC is highly variable. Predictive biomarkers such as HER-2 and Survivin may have the potential to predict treatment response and prognosis. This study aims to analyze the relationship between Survivin and HER-2 expression and the clinical response toNACTin LABC patients. Methods: In this prospective cohort study, we enrolled 56 female LABC patients scheduled for a Taxane, Adriamycin, and CyclophosphamideNACT regimen. Pre-treatment biopsy tissues were examined for Survivin and HER-2 expression via immunohistochemistry. Clinical response was evaluated after three cycles using the RECIST criteria. Data were analyzed using the Chi-Square test and multivariate logistic regression. Results: High Survivin expression was found in 32/56 (57.1%) participants and positive HER-2 expression in 28/56 (50%) . A significant correlation was found between high Survivin expression and HER-2 positivity (p=0.007) . High Survivin expression (p\u003C0.001; PR=4.688; 95% CI: 1.881–11.682) and HER-2 positivity (p\u003C0.001; PR=5.585; 95% CI: 2.227–14.012) were significantly associated with poor chemotherapy response (non-response) . Multivariate analysis showed that Survivin (OR=0.032; p=0.002) and HER-2 (OR=0.022; p=0.001) were significant independent predictors of chemotherapy response. Conclusion: Survivin and HER-2 expression are significantly associated and serve as independent predictors of poor response to NACT in LABC patients. Evaluation of these biomarkers could be crucial in risk stratification and the personalization of therapy.  \nKeywords: Breast Neoplasms-Neoadjuvant Chemotherapy-Survivin-HER-2 Receptors-Predictive Biomarkers  \nAsian Pac J Cancer Prev, 27 (2), 569-573  \nIntroduction  \nBreast cancer is the malignancy with the highest incidence in women, both globally and in Indonesia, posing a significant public health challenge [1, 2] . Local data in Makassar show breast cancer as the cancer with the highest incidence and the second leading cause of death [3]. A particularly challenging subgroup in management is locally advanced breast cancer (LABC), characterized by tumor infiltration into surrounding tissues and a high risk of recurrence [4, 5] . The standard management strategy for LABC is neoadjuvant chemotherapy (NACT), which aims to reduce tumor size (downsizing), thereby enabling breast-conserving surgery or surgery with tumor-free margins [5, 6] .  \nThe success of NACT, often measured by clinical or pathological response, varies widely among patients [7] .  \nTherefore, identifying reliable predictive biomarkers is critical for selecting patients who are most likely to benefit from NACT and for guiding therapeutic decisions [5, 7, 8] .  \nHuman Epidermal Growth Factor Receptor 2 (HER-2) is an established prognostic and predictive biomarker. HER-2 overexpression correlates with aggressive tumor behavior but also serves as a target for specific therapies that can increase the pathological complete response (pCR) rate when combined with chemotherapy [9–11] . In addition to HER-2, Survivin, a member of the inhibitor of apoptosis (IAP) family, has emerged as a promising biomarker [12–14] . Survivin regulates cell division and inhibits apoptosis and is frequently overexpressed in breast cancer, where it is hypothesized to confer resistance to chemotherapy [15, 16] . Survivin overexpression is hypothesized to contribute to cancer c","cbCainj8X4lLtHw1","https://ap.wps.com/l/cbCainj8X4lLtHw1","pdf",286371,"English","# Abstract\n# Introduction\n# Materials and Methods","[{\"question\":\"What is the main purpose of the study?\",\"answer\":\"To analyze the relationship between Survivin and HER-2 expression and the clinical response to NACT in locally advanced breast cancer patients.\"},{\"question\":\"How were Survivin and HER-2 expression levels measured?\",\"answer\":\"Pre-treatment biopsy tissues were examined for Survivin and HER-2 expression using immunohistochemistry.\"},{\"question\":\"How was treatment response assessed after NACT?\",\"answer\":\"Clinical response was evaluated after three chemotherapy cycles using the RECIST criteria.\"}]","Expression of Survivin and HER-2 as Independent Predictive Factors for Treatment Response in Locally Advanced Breast Cancer - A Prospective Cohort Study | PDF",1790084315,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2584a5a48469f3fe0e61872f3c54da51.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/506561a1502329ee5676a641afde20fa.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a79e1f583cc5e24b13d40f72f3897a86.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c840fa8e8ff894fd675c77786930d689.webp",980,1385]